(Reuters) – Drug developer Generate:Biomedicines, which uses artificial intelligence (AI) to find new treatments, said on Thursday it has raised $273 million from investors including …
CHICAGO (Reuters) – The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he …
By Blake Brittain (Reuters) – Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that barred generic versions of its blockbuster psoriasis …
(Reuters) -Amgen Inc is in advanced talks to buy biotech company Horizon Therapeutics Plc, the Wall Street Journal reported on Sunday, while rival bidder French …
By Deena Beasley LOS ANGELES (Reuters) – Amgen Inc’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a …
By Deena Beasley (Reuters) – Amgen Inc’s Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with …
By Michael Erman NEW YORK – The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen …
By Nancy Lapid (Reuters) – The following are summaries of some of the cancer research advances being presented the annual meeting of the American Society …